Expert opinion on investigational drugsHumansColorectal NeoplasmsProto-Oncogene Proteins p21(ras)Molecular Targeted TherapyAnimals
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.
Shadi Chamseddine, Asfar Azmi, Muhammad Wasif Saif
Published: 202510.1080/13543784.2025.2611395
Abstract
INTRODUCTION: KRAS mutations are among the most common oncogenic alterations in colorectal cancer (CRC). These mutations play a central role in tumor initiation and progression through activation of the MAPK signaling pathway. For many years, KRAS wa…
Preview only. Read the full abstract at the source